Almost every patient who asks you about hormone therapy is working from information that is either two decades old or actively promotional. Correcting that is now part of the clinical task, and it takes longer than the prescribing decision itself. This article summarizes where the evidence sits, what changed, and what patients most commonly believe that is not accurate.
Article Summary:
| Two decades of prescribing behavior were shaped by an interpretation of the Women’s Health Initiative that the data did not support. |
| Timing of initiation is central to the risk and benefit balance, and it is the part most often missing from patient understanding. |
| Patients arrive with fear in one direction and marketing in the other. Both require correcting. |
| There is no need to wait twelve months without a period before treating symptoms. |
What actually happened with the Women’s Health Initiative
Before the WHI findings were published, around 40 percent of postmenopausal women in the United States were using hormone therapy. Prescribing collapsed afterward and stayed low for close to twenty years.
The trial was designed to test whether hormone therapy could prevent cardiovascular disease, and it enrolled a population substantially older than the patients who typically present with menopausal symptoms. When the data were analyzed, starting hormone therapy later in life was associated with increased cardiovascular risk in the first six to twelve months.
A small increase in breast cancer risk was identified with combined oral estrogen and progestin, in the region of one additional case per 1,000 women per year, appearing after several years of use. That was widely reported as a doubling of risk, which is arithmetically true and clinically misleading.
The effect on practice went well beyond prescribing. Education thinned, research narrowed, and clinicians trained in that period received very little instruction in this area.
What reanalysis and subsequent evidence established
The central finding is that timing matters. The balance of benefit and risk differs substantially between initiation during the menopausal transition or the early postmenopausal years and initiation at 60 or 65, when the body has adapted to low estrogen. This is usually referred to as the timing hypothesis.
Route and formulation also matter, as does the presence or absence of a uterus, personal and family history, and cardiovascular and thrombotic risk. There is no single risk figure that applies to hormone therapy as a category, which is precisely why category-level statements, in either direction, are unhelpful.
What patients typically believe
Three beliefs come up repeatedly and each is worth addressing directly.
That hormone therapy causes breast cancer, full stop. That vaginal estrogen carries the same risks as systemic therapy, which keeps patients away from a local treatment with a different profile and reassuring evidence. And that they must wait until twelve months have passed without a period before anything can be done.
That last belief deserves particular attention because it is often reinforced by clinicians. There is no basis for requiring a patient to be symptomatic for a year before treatment. The right time to treat is when a patient has symptoms and wants treatment.
What has changed recently
Local vaginal estrogen carried a boxed warning for many years which many clinicians considered unsupported by the evidence for local treatment. The FDA began removing these warnings in November 2025, and labeling has been updating since. Patients previously steered away from local estrogen on the basis of that label may reasonably reconsider.
Non-hormonal prescription options have also expanded, including medications acting on the brain pathway involved in vasomotor symptoms rather than on hormones. One of these carries a warning regarding rare but serious liver injury and requires liver function testing before initiation and periodically during treatment. If you offer it, that monitoring needs to be built into your pathway rather than remembered.
How to frame the conversation
The most useful stance is inclusive about options and explicit about uncertainty. Present what is known, say plainly where the evidence is thinner, particularly on long-term outcomes for some interventions, and let the patient’s goals and history determine the choice.
Patients also have positions of their own, and some of those are firm. A patient who says she will never use hormones, or never an intrauterine device, is entitled to that. Asking why can be informative, since the objection is sometimes based on an experience or an assumption that no longer applies, but the answer belongs to her.
A trial is often the most productive next step. The patient knows how she feels now and will know how she feels afterward. The working standard is that everything should feel better and nothing should feel worse; if that is not the case, the plan changes.
What this asks of a practice
Prescribing competently in this area requires understanding the evidence well enough to explain it, not just to apply a protocol. It also requires the time to have the conversation, and documentation that reflects what was discussed.
This is the substance of EncorVita’s treatment education, including candidate identification, formulation and route selection, and the long-term implications that follow the prescribing decision. Program details are at academy.encorvita.com.
Combined oral estrogen and progestin was associated with a small increase in risk, in the region of one additional case per 1,000 women per year, emerging after several years of use. Risk varies by formulation, route, duration and individual history, so category-level statements are not accurate.
The observation that the balance of benefit and risk differs according to how long after menopause therapy is started, with initiation during the transition or early postmenopause differing substantially from initiation at 60 or older.
No. Symptoms can be treated during perimenopause. There is no clinical basis for requiring a year of amenorrhea before offering relief.
No. It acts locally with minimal systemic absorption. The FDA began removing the historic boxed warnings from these products in November 2025.
Certain antidepressants, gabapentin, and newer agents acting on the brain pathway involved in vasomotor symptoms. One of the newer agents requires liver function monitoring before and during treatment.
There is no arbitrary stopping point. Continuation is reviewed periodically against symptoms, goals and current risk profile.
The symptom assessment, relevant personal and family history, the options discussed including alternatives, the rationale for the choice made, and the planned review interval.
